Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL4 vs QL1 Block for Pain in Open Nephrectomy
NCT06889987Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (3 arms), sponsored by National Cancer Institute. Primary endpoint: Degree of pain. Started Dec 2024; status: recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06889987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889987.